Zoetis indicated this during its Q1 as well as Q2′ 2026 Earnings Discussions that Pet Parents Visits to Vets consequent to Vet Services Affordability is an emerging pain point for whole of Companion Animals segment. This now gets endorsed by recent release by Pawlicy Advisors’ State of the Industry Report released this week.
Veterinary affordability is emerging as a structural issue for the U.S. companion-animal healthcare market, with new data showing that financial constraints are increasingly influencing treatment recommendations, client decisions and, in some cases, end-of-life care.
The latest State of the Industry: The Impact of Pet Insurance on U.S. Veterinary Practices in 2026, produced by Pawlicy Advisor in collaboration with the American Animal Hospital Association (AAHA), surveyed 451 veterinary professionals in May and June 2026. The third edition of the survey shows that affordability is no longer an occasional client-service problem; it is becoming part of routine clinical decision-making.
Cost Is Now Influencing Treatment Plans on a Weekly Basis
The strongest finding is the frequency with which financial considerations affect clinical recommendations.
86.1% of veterinary professionals said they adjust a recommended treatment plan at least once a week because of client cost concerns. Respondents reported that this happens approximately five times per week, up from 4.7 times in the previous survey.
Financial conversations are similarly frequent. 81.3% of respondents said they have at least one difficult cost-of-care conversation every week, with an average of 4.4 such conversations per week, compared with four in the previous year’s survey.
This distinction is important. The issue is not simply that veterinary services have become more expensive. The survey suggests that price is increasingly entering the clinical pathway before treatment is delivered.
In practical terms: Clinical recommendation → treatment estimate → affordability assessment → modification or rejection of care
That creates a different operating environment for veterinary practices, pharmaceutical companies, diagnostic providers and pet-health insurers.
The $1,000 Threshold Is Emerging as a Significant Affordability Barrier
The survey introduced a particularly important measure in 2026: the point at which veterinary professionals observe owners declining recommended treatment.
85% of respondents said they see pet owners decline recommended care when the cost reaches $1,000 or less.
The pressure begins even below that level. According to AAHA’s summary of the findings, 47% of practitioners see clients decline services at $500 because of cost.
This matters because $500–$1,000 is not necessarily the cost of highly specialized veterinary medicine.
A diagnostic work-up, hospitalization, foreign-body surgery or other relatively common acute-care episode can reach these levels. Pawlicy Advisor noted that multi-step diagnostics, foreign-body surgery and several days of hospitalization can routinely exceed $1,000.
The result is a widening gap between what veterinary medicine can clinically offer and what some owners are financially able or willing to purchase.
Economic Euthanasia Remains a Serious Consequence
The most concerning finding relates to euthanasia. Veterinary professionals estimated that, on average, 13% of euthanasia decisions are driven by an owner’s inability to afford treatment. Nearly one in four respondents (22.9%) said that financial constraints account for 20% or more of euthanasia decisions in their own practice.
These figures should be interpreted carefully. The survey does not establish that affordability is the sole reason for these euthanasia decisions, nor does it provide a clinical audit of individual cases. They are professional estimates reported by survey respondents. Nevertheless, the scale is commercially and ethically significant.
If a material proportion of veterinary teams regularly encounter cases where clinically appropriate treatment is financially inaccessible, affordability becomes more than a customer-service issue. It becomes an access-to-care issue.
Pet Insurance Shows a Clear Association With Treatment Acceptance
The survey also provides evidence that financial protection may influence the ability of clients to proceed with recommended care.
87.1% of veterinary professionals agreed that pet insurance helps clients say “yes” to more care. Among respondents who observed differences in insured patients, 73% reported better treatment compliance, 49.9% reported better outcomes, and 35.2% reported less economic euthanasia.
These are reported observations from veterinary professionals rather than randomized evidence that insurance itself causes better outcomes. That distinction is important.
However, the consistency of the responses points toward a plausible commercial relationship: Financial protection → fewer cost barriers → greater ability to accept recommended treatment → potentially better continuity of care.
The Insurance Gap Remains Large
Despite the apparent value veterinary professionals place on insurance, adoption remains low. Only 48.2% of veterinary practices surveyed said they proactively recommend pet insurance. Many practices wait until clients raise the subject themselves.
The survey found a striking difference in reported insurance penetration:
Practice approach |
Median share of insured patients |
|---|---|
Proactively recommends pet insurance |
7.5% |
Discusses insurance only when clients ask |
3.5% |
U.S. pet population benchmark |
4.27% |
Practices that proactively recommend insurance therefore reported a median insured-patient share of approximately 2.1 times that of practices that wait for clients to ask. This is an association rather than proof that recommendation alone causes higher insurance penetration. Nevertheless, the relationship is commercially significant.
U.S. Pet Insurance Is Growing — but Most Pets Remain Uninsured
The broader insurance market reinforces the opportunity. The North American Pet Health Insurance Association (NAPHIA) reported that 7.6 million pets were insured in North America at the end of 2025, up from 7.03 million in 2024, representing an 8.5% increase.
Yet U.S. penetration remains low. NAPHIA’s 2026 data puts the proportion of U.S. pets covered by insurance at approximately 4.27%. That means more than 95% of U.S. pets remain uninsured.
The implication is straightforward: the insurance market is expanding rapidly from a relatively small base, while a very large uninsured population remains exposed to unexpected veterinary costs.
This creates a potentially important feedback loop for the veterinary sector.
Low insurance penetration → high out-of-pocket exposure → treatment deferral or rejection → pressure on practices → stronger incentive to discuss financial planning and insurance.
This Is Bigger Than Pet Insurance
The most important industry conclusion from the survey is therefore not simply that pet insurance has growth potential. The deeper issue is financial access to veterinary medicine.
Veterinary medicine has become increasingly capable of providing advanced diagnostics, surgery, oncology, cardiology, imaging, chronic disease management and specialized therapeutics. But the ability to deliver those services depends partly on whether the owner can finance them.
This creates a growing disconnect: Clinical capability does not automatically translate into clinical access.
For veterinary practices, that can mean more treatment-plan modification, more difficult financial discussions and greater pressure to explain treatment choices in terms of both clinical benefit and cost. For pet owners, it can mean choosing between a full diagnostic work-up, a lower-cost alternative, delayed treatment or no treatment.
For the animal-health industry, it creates a different commercial question: How can innovation reach the patient if affordability prevents adoption?
Implications for Animal-Health Companies
The affordability data could have consequences well beyond insurance.
1. Therapeutics may increasingly need an economic-value proposition – Veterinary pharmaceutical companies traditionally compete on efficacy, safety, convenience and duration of action.
Cost is becoming an additional part of the value equation. Products that reduce hospitalization, decrease treatment frequency, improve compliance or avoid more expensive downstream interventions may become easier for veterinarians to justify to cost-sensitive clients.
The commercial conversation may increasingly shift from: “Does this product work?”
to: “What does this treatment deliver relative to the total cost of managing the disease?”
2. Diagnostics face the same affordability test – Diagnostics can improve clinical decision-making, but diagnostic utilization can also be affected by price.
If owners decline care at $500 or $1,000, veterinary practices may face pressure to prioritize diagnostic tests based not only on clinical value but also on affordability. The commercial opportunity is not necessarily to make veterinary medicine “cheap.” It is to make high-value clinical decisions more financially accessible.
3. Preventive care could become more strategically important – Affordability also strengthens the case for prevention. A lower-cost vaccination, parasite-control, dental-health, weight-management or screening intervention may prevent a much more expensive clinical event later.
That does not mean preventive care will replace advanced therapeutics. Rather, the economic pressure could encourage a more explicit continuum: Prevention → early detection → lower-cost intervention → advanced treatment when necessary.
This could benefit companies positioned around preventive health, diagnostics, nutrition, chronic disease management and early intervention.
4. Insurance could become part of the veterinary-care pathway
Pet insurance has traditionally been treated as an insurance product. The latest data suggests it is increasingly relevant to the delivery of veterinary medicine itself. If insured clients are more capable of accepting recommended care, insurance can influence: treatment compliance; diagnostic uptake; access to specialist care; ability to finance surgery; chronic disease management and economic euthanasia decisions.
That makes insurers, veterinary practices and animal-health companies increasingly interconnected.
What the Data Means for Veterinary Practices
For veterinary practices, the report suggests that affordability should increasingly be treated as an operational issue rather than something discussed only when a client rejects an estimate.
Potential practice responses include:
-
Discuss financial planning earlier — before a major disease event occurs.
-
Present clinically appropriate options clearly where alternatives genuinely exist.
-
Explain the economic value of prevention.
-
Make insurance education part of the client journey, while avoiding inappropriate insurance advice outside the team’s licensing or competence.
-
Use transparent estimates so owners understand potential costs.
-
Develop payment or financing pathways where available.
-
Track declined-care patterns to identify recurring affordability barriers.
